secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001437749-24-017132
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed reports Q1 net income $2.5M; DLB trial enrollment on track for Q2 2024
-------------------------------------------------------------------------------

- Cash $6.4M as of March 31; plus $50M upfront from private placement closed April 1 provides runway through end 2025.
- RewinD-LB Phase 2b enrollment on track to complete in Q2 2024; topline data expected Q4 2024.
- Net income $2.5M in Q1 vs net loss $0.5M in Q1 2023; operating loss widened to $2.6M from $1.4M.
- Grant revenue from NIA $2.3M in Q1 vs $1.4M; R&D expenses increased to $2.8M.
- Up to $149.4M private placement with leading healthcare investors; $50M gross upfront.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924017132/0001437749-24-017132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924017132/crvo20240515_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-017132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer